Use of antiosteoporotic medication in the Danish ROSE population-based screening study

M. P. Højberg; K. H. Rubin; T Holmberg; S Rothmann; S Möller; J Gram; Mickael Bech; K. Brixen; A. P. Hermann

doi:10.1007/s00198-019-04934-7

Use of antiosteoporotic medication in the Danish ROSE population-based screening study

M. P. Højberg
, K. H. Rubin
, T Holmberg
, S Rothmann
, S Möller
, J Gram
, Mickael Bech
, K. Brixen
, A. P. Hermann

University of Southern Denmark
VIVE - Det Nationale Forsknings- og Analysecenter for Velfærd
Odense University Hospital

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment.

Original language	English
Journal	Osteoporosis International
Pages (from-to)	1223-1233
ISSN	0937-941X
DOIs	https://doi.org/10.1007/s00198-019-04934-7
Publication status	Published - Mar 2019
Externally published	Yes

Access to Document

10.1007/s00198-019-04934-7

Cite this

@article{d861f01b941a4ea7aa77457e2b594c9c,

title = "Use of antiosteoporotic medication in the Danish ROSE population-based screening study",

abstract = "Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment.",

author = "H{\o}jberg, \{M. P.\} and Rubin, \{K. H.\} and T Holmberg and S Rothmann and S M{\"o}ller and J Gram and Mickael Bech and K. Brixen and Hermann, \{A. P.\}",

year = "2019",

month = mar,

doi = "10.1007/s00198-019-04934-7",

language = "English",

pages = "1223--1233",

journal = "Osteoporosis International",

issn = "0937-941X",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Use of antiosteoporotic medication in the Danish ROSE population-based screening study

AU - Højberg, M. P.

AU - Rubin, K. H.

AU - Holmberg, T

AU - Rothmann, S

AU - Möller, S

AU - Gram, J

AU - Bech, Mickael

AU - Brixen, K.

AU - Hermann, A. P.

PY - 2019/3

Y1 - 2019/3

N2 - Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment.

AB - Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment.

U2 - 10.1007/s00198-019-04934-7

DO - 10.1007/s00198-019-04934-7

M3 - Journal article

SN - 0937-941X

SP - 1223

EP - 1233

JO - Osteoporosis International

JF - Osteoporosis International

ER -